Nola K M, Gourley D R, Portner T S, Gourley G K, Solomon D K, Elam M, Regel B
Immunex Corporation, Nashville, TN 37221, USA.
J Am Pharm Assoc (Wash). 2000 Mar-Apr;40(2):166-73. doi: 10.1016/s1086-5802(16)31060-9.
To identify patients at risk for coronary artery disease (CAD) through a search of a community pharmacy's prescription database, to screen and identify patients with elevated cholesterol and at risk for CAD, to enroll patients in a pharmacist-directed lipid management program, and to evaluate selected clinical and humanistic outcomes.
Randomized, pretest-posttest control groups.
Independent community pharmacy in a suburban metropolitan area.
51 patients who were not at National Cholesterol Education Program low-density lipoprotein cholesterol (LDL-C) or defined triglyceride goals and who met inclusion criteria.
Pharmacist-directed lipid management program.
Clinical outcome measures included total cholesterol, LDL-C, high-density lipoprotein cholesterol (HDL-C), and triglyceride levels; achievement of LDL-C goal; and risk factor prediction scores. Humanistic outcome measures included patient satisfaction with pharmaceutical care and patient knowledge of hyperlipidemia.
LDL-C was decreased in the pharmacist intervention group (n = 25), compared with an increase in the control group at study end. HDL-C levels increased and triglyceride levels decreased in both groups. Of treatment group patients, 32% achieved their cholesterol goals, compared with 15% of control group patients. Risk factor prediction scores improved in the treatment group and worsened in the control group. The treatment group's hyperlipidemia knowledge scores improved significantly from pretest to posttest. Both treatment and control group patient satisfaction scores for the pharmacist investigator were favorable at study end.
Both treatment and control patients benefited from participating in this study. Patients enrolled in the lipid management program made greater improvements in their knowledge of hyperlipidemia, risk factor scores, and cholesterol levels.
通过检索社区药房的处方数据库来识别有冠状动脉疾病(CAD)风险的患者,筛查并识别胆固醇升高且有CAD风险的患者,让患者参加由药剂师指导的血脂管理项目,并评估选定的临床和人文结局。
随机、前后测对照组。
大都市郊区的独立社区药房。
51名未达到国家胆固醇教育计划低密度脂蛋白胆固醇(LDL-C)或规定甘油三酯目标且符合纳入标准的患者。
由药剂师指导的血脂管理项目。
临床结局指标包括总胆固醇、LDL-C、高密度脂蛋白胆固醇(HDL-C)和甘油三酯水平;LDL-C目标的达成情况;以及风险因素预测评分。人文结局指标包括患者对药学服务的满意度和患者对高脂血症的知晓情况。
在研究结束时,药剂师干预组(n = 25)的LDL-C有所下降,而对照组则有所上升。两组的HDL-C水平均升高,甘油三酯水平均下降。治疗组患者中有32%达到了胆固醇目标,而对照组患者中这一比例为15%。治疗组的风险因素预测评分有所改善,而对照组则恶化。治疗组的高脂血症知识评分从测试前到测试后有显著提高。在研究结束时,治疗组和对照组患者对药剂师研究者的满意度评分都很高。
治疗组和对照组患者都从参与本研究中获益。参加血脂管理项目的患者在高脂血症知识、风险因素评分和胆固醇水平方面有更大改善。